Clinical Trials Browser

Unknown × OTHER × aflutinib × Clear all

NCT05987826 2023-08-14

Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04895930 2023-01-06

FOCUS-A

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05548348 2022-09-21

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05255406 2022-08-04

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Phase 2/3 Unknown

NSCLC

NCT05165355 2022-01-18

ATHEM

Phase 2 Unknown

NSCLC

NCT05079022 2021-10-15

ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Phase 1/2 Unknown

Adenocarcinoma of Lung, Neoplasm, Residual

NCT04982900 2021-10-05

TERMGGO

Phase 2 Unknown

Multiple Primary Lung Cancers

NCT04970693 2021-07-21

A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung